Tumour evolution, which results in the existence of multiple distinct populations of cancer cells within the same tumour and the same patient, is increasingly appreciated to have a key role in drug resistance. In this article, we discuss the implications for drug development, including approaches to reduce the likelihood of the emergence of drug resistance.
This is a preview of subscription content, log in via an institution to check access.
References
Turajlic, S. & Swanton C. Metastasis as an evolutionary process. Science 352, 169–175 (2016).
McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613–628 (2017).
Bozic, I. & Nowak, M. A. Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proc. Natl Acad. Sci. USA 111, 15964–15968 (2014).
Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 7, 264–276 (2016).
Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Turajlic, S., Swanton, C. Implications of cancer evolution for drug development. Nat Rev Drug Discov 16, 441–442 (2017). https://doi.org/10.1038/nrd.2017.78
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.78
- Springer Nature Limited
This article is cited by
-
Cancer biology deciphered by single-cell transcriptomic sequencing
Protein & Cell (2022)
-
TRACERx Renal: tracking renal cancer evolution through therapy
Nature Reviews Urology (2017)